This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2017 Nov 23;377(21):2085-2088.

doi: 10.1056/NEJMe1712335. Epub 2017 Nov 3.

CFTR Modulator Therapy for Cystic Fibrosis

Hartmut Grasemann¹

Affiliations

PMID: 29099349
DOI: 10.1056/NEJMe1712335

Editorial

CFTR Modulator Therapy for Cystic Fibrosis

Hartmut Grasemann. N Engl J Med. 2017.

. 2017 Nov 23;377(21):2085-2088.

doi: 10.1056/NEJMe1712335. Epub 2017 Nov 3.

Author

Hartmut Grasemann¹

Affiliation

¹ From the Division of Respiratory Medicine, Department of Pediatrics, the Hospital for Sick Children and University of Toronto, Toronto.

PMID: 29099349
DOI: 10.1056/NEJMe1712335

No abstract available

PubMed Disclaimer

Comment on

Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.
Rowe SM, Daines C, Ringshausen FC, Kerem E, Wilson J, Tullis E, Nair N, Simard C, Han L, Ingenito EP, McKee C, Lekstrom-Himes J, Davies JC. Rowe SM, et al. N Engl J Med. 2017 Nov 23;377(21):2024-2035. doi: 10.1056/NEJMoa1709847. Epub 2017 Nov 3. N Engl J Med. 2017. PMID: 29099333 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- Genetic Alliance
- MedlinePlus Health Information